Login or Register to unlock everything MedSchool has to offer!
 
 

Read More...

The information in this section has been adapted in part from the Australian Therapeutic Goods Association website's repository of product information documents, which are available at https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI.
 Bell RG, Sadowski JA, Matschiner JT. Mechanism of action of warfarin: Warfarin and metabolism of vitamin K1. Biochemistry. 1972, 11(10): 1959-1961. Blann AD, Landray MJ, Lip GYH. An overview of antithrombotic therapy. BMJ?: British Medical Journal. 2002;325(7367):762-765. Collen D, Lijnen HR. The tissue-type plasminogen activator story. Arteriosclerosis, thrombosis, and vascular biology. 2009 Aug 1;29(8):1151-5. Coukell AJ, Markham A. Clopidogrel. Drugs. 1997 Nov, 54(5): 745-750. Dobesh PP, Oestreich JH. Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety. Pharmacotherapy. 2014;34(10):1077-1090. Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2009 Sep 1;29(9):1089-102. Fitzgerald GA. Dipyridamole. N Engl J Med 1987; 316:1247-1257. Hanley JP. Warfarin Reversal. Journal of Clinical Pathology. 2004, 57: 1132-1139. Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thrombosis Research. 1983 Dec 31;29:39-46. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: heparin a statement for healthcare professionals from the american heart association. Arteriosclerosis, thrombosis, and vascular biology. 2001 Jul 1;21(7):e9. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: Mechanism of Action, Pharmacokinetics, Dosing Considerations, Monitoring, Efficacy, and Safety. Chest. 1995, 108(4 Suppl): 258S-275S. Hoak JC, Mechanisms of action: Aspirin. Thrombosis Research. 1983, 29(1 Suppl): 47-51. Johnston-Cox HA, Ravid K. Adenosine and blood platelets. Purinergic Signalling. 2011;7(3):357-365. McCormack PL. Tranexamic Acid. Drugs. 2012 March; 72(5): 585-617. Okajima Y, Kanayama S, Maeda Y, Urano S, Kitani T, Watada M, Nakagawa M, Ijichi H. Studies on the neutralizing mechanism of antithrombin activity of heparin by protamine. Thrombosis Research. 1981; 24(2): 21-29. Park BK. Warfarin: Metabolism and Mode of Action. Biochemical Pharmacology. 1988 Jan, 37(1): 19-27. Pollack Jr CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J. Idarucizumab for dabigatran reversal. New England Journal of Medicine. 2015 Aug 6;373(6):511-20. Scarborough RM, Kleiman NS, Phillips DR. Platelet Glycoprotein IIb/IIIa Antagonists What Are the Relevant Issues Concerning Their Pharmacology and Clinical Use?. Circulation. 1999 Jul 27;100(4):437-44. Schneider DJ. Anti-platelet therapy: glycoprotein IIb-IIIa antagonists. British Journal of Clinical Pharmacology. 2011;72(4):672-682. Schrör K. Clinical pharmacology of the adenosine diphosphate (ADP) receptor antagonist, clopidogrel. Vascular Medicine. 1998 Aug 1;3(3):247-51. Sherry S. Fibrinolytic agents. Disease-a-Month. 1969 May, 15(5): 1-32. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA. Andexanet alfa for the reversal of factor Xa inhibitor activity. New England Journal of Medicine. 2015 Dec 17;373(25):2413-24. Tadros R, Shakib S. Warfarin: Indications, Risks and Drug Interactions. Australian Family Physician. 2010 Jul, 39(7): 476-479. Van Veen JJ, Maclean RM, Hampton KK, Laidlaw S, Kitchen S, Toth P, Makris M. Protamine Reversal of Low Molecular Weight Heparin: Clinically Effective?. Blood Coagulation & Fibrinolysis. 2011 Oct, 22(7): 565-570. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation. 2010 Jul 27;122(4):394-403.
Feedback